State Street’s Neuropace NPCE Stock Holding History
Bought
Maintained
Sold
Other funds holding NPCE
PCH
SCM
FLAM
O
DCM
VCM
AC
State Street's NPCE Position: Q1 2026 in Review
State Street increased its Neuropace (NPCE) stake by 11% in Q1 2026, buying an estimated $745K and bringing the position to 497,546 shares worth $6.54M. The position accounts for ﹤0.01% of the portfolio, ranked #2823.
State Street first reported a position in NPCE in Q2 2021 and has held it in 20 quarters since. The position peaked at $6.92M in Q4 2025. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.
- State Street held 497,546 shares of Neuropace worth $6.54M as of Q1 2026.
- State Street bought 49,682 Neuropace shares in Q1 2026, an estimated $745K.
- Neuropace made up ﹤0.01% of State Street's portfolio in Q1 2026, its #2823 holding.
- State Street first reported a position in Neuropace in Q2 2021 and has held it in 20 quarters since.
- State Street's Neuropace position peaked at $6.92M in Q4 2025.
- 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.
Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.